2013, Number 5
<< Back Next >>
Rev Invest Clin 2013; 65 (5)
Enfermedad pulmonar intersticial (EPI) en artritis reumatoide (AR)
Rojas-Serrano J, Gaxiola M, Mejía M
Language: Spanish
References: 8
Page: 457-458
PDF size: 91.75 Kb.
Text Extraction
No abstract.
REFERENCES
Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359(9313): 1173-7.
Landewe RB. Methotrexate saves lives: a pearl of observational research. Arthritis Rheum 2013; 65(2): 307-09.
Wasko MC, Dasgupta A, Hubert H, Fries JF, Ward MM. Propensity- adjusted association of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum 2013; 65(2): 334-42.
Saravanan V, Kelly C. Drug-related pulmonary problems in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006; 45(7): 787-9.
Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 2006; 54(5): 1435-9.
Wolfe F, Caplan L, Michaud K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand J Rheumatol 2007; 36(3): 172-8.
Fischer A, Brown KK, Du Bois RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 2013; 40(5): 640-06.
Jorge R, Mayra M, Renzo P. Rheumatoid arthritis-associated interstitial lung disease: inflammation evaluated with high resolution computed tomography scan is correlated to rheumatoid arthritis disease activity. B49. Progress in connective tissue disease related to interstitial lung disease. American Thoracic Society 2013: A2910.
Full text